Federated Hermes
IBRX icon

Federated Hermes’s ImmunityBio IBRX Stock Holding History

Federated Hermes’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15M Buy
1,713,200
+326,609
+24% +$2.47M 0.02% 571
2026
Q1 		$10.6M Buy
+1,386,591
New +$9.49M 0.02% 616
2024
Q2 		– Sell
-198
Closed -$1.06K – 2079
2024
Q1 		$1.06K Buy
198
+1
+0.5% +$5 ﹤0.01% 1959
2023
Q4 		$989 Sell
197
-63
-24% -$198 ﹤0.01% 1974
2023
Q3 		$439 Sell
260
-15,495
-98% -$31.1K ﹤0.01% 2046
2023
Q2 		$43.8K Sell
15,755
-6,252
-28% -$17.7K ﹤0.01% 1694
2023
Q1 		$40.1K Buy
+22,007
New +$68.4K ﹤0.01% 1755
2022
Q2 		– Sell
-1,998
Closed -$11K – 2215
2022
Q1 		$11K Buy
1,998
+3
+0.2% +$18 ﹤0.01% 1876
2021
Q4 		$12K Sell
1,995
-2,529
-56% -$19K ﹤0.01% 1913
2021
Q3 		$44K Sell
4,524
-34
-0.7% -$374 ﹤0.01% 1874
2021
Q2 		$65K Buy
4,558
+4,466
+4,854% +$73.8K ﹤0.01% 1840
2021
Q1 		$2K Buy
+92
New +$2.38K ﹤0.01% 2126
2020
Q3 		– Sell
-175
Closed -$2K – 2299
2020
Q2 		$2K Buy
+175
New +$988 ﹤0.01% 2082
2020
Q1 		– Sell
-898
Closed -$3K – 2289
2019
Q4 		$3K Hold
898
– – ﹤0.01% 1999
2019
Q3 		$1K Sell
898
-1,903
-68% -$2.36K ﹤0.01% 2106
2019
Q2 		$3K Hold
2,801
– – ﹤0.01% 2046
2019
Q1 		$4K Hold
2,801
– – ﹤0.01% 1998
2018
Q4 		$3K Buy
2,801
+915
+49% +$2.09K ﹤0.01% 2045
2018
Q3 		$7K Sell
1,886
-156
-8% -$493 ﹤0.01% 2003
2018
Q2 		$6K Buy
2,042
+512
+33% +$1.9K ﹤0.01% 1991
2018
Q1 		$6K Sell
1,530
-279
-15% -$1.22K ﹤0.01% 1950
2017
Q4 		$8K Buy
1,809
+239
+15% +$1.13K ﹤0.01% 1919
2017
Q3 		$9K Buy
1,570
+855
+120% +$5.27K ﹤0.01% 1860
2017
Q2 		$5K Buy
+715
New +$3.09K ﹤0.01% 1947

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes's IBRX Position: Q2 2026 in Review

Federated Hermes increased its ImmunityBio (IBRX) stake by 24% in Q2 2026, buying an estimated $2.47M and bringing the position to 1,713,200 shares worth $15M. The position accounts for 0.02% of the portfolio, ranked #571.

Federated Hermes first reported a position in IBRX in Q2 2017 and has held it in 24 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Federated Hermes held 1,713,200 shares of ImmunityBio worth $15M as of Q2 2026.
  • Federated Hermes bought 326,609 ImmunityBio shares in Q2 2026, an estimated $2.47M.
  • ImmunityBio made up 0.02% of Federated Hermes's portfolio in Q2 2026, its #571 holding.
  • Federated Hermes first reported a position in ImmunityBio in Q2 2017 and has held it in 24 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.